Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Colombo

Showing results (141-150 of 372) with videos related to

Pageof 38
Sort By:
Expert Opinion on Biological Therapy|December 23, 2011
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical managementMauro Viganò, Elisabetta Degasperi, Alessio Aghemo, et al.
Journal of Hepatology|September 25, 2009
HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis CStella De Nicola, Alessio Aghemo, Maria Grazia Rumi, et al.
Thrombosis Research|October 20, 2006
Endothelial protein C receptor plasma levels increase in chronic liver disease, while thrombomodulin plasma levels increase only in hepatocellular carcinomaEugenia Biguzzi, Franca Franchi, Paolo Bucciarelli, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 12, 2020
A letter of solidarity during the COVID-19 pandemicJeffrey V Lazarus, Francesco Negro, Manal El-Sayed, et al.
Hepatology (Baltimore, Md.)|September 3, 2010
Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapyAlessio Aghemo, Maria Grazia Rumi, Stella De Nicola, et al.
Hepatology (Baltimore, Md.)|January 30, 2009
The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?Alessio Aghemo, Maria Grazia Rumi, Gian Maria Prati, et al.
Seminars in Liver Disease|February 29, 2020
Postsustained Virological Response Management in Hepatitis C PatientsChiara Masetti, Ana Lleo, Matteo Colombo, et al.
Expert Review of Anti-Infective Therapy|May 1, 2013
PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year historyElisabetta Degasperi, Mauro Viganò, Alessio Aghemo, et al.
Therapeutic Advances in Medical Oncology|July 20, 2019
The risk of liver cancer in autoimmune liver diseasesAna Lleo, Ynto S de Boer, Rodrigo Liberal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 19, 2016
Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literatureRoberta D'Ambrosio, Alessio Aghemo, Valeria Rossetti, et al.
Pageof 38

Showing results (141-150 of 372) with videos related to

Sort By:
Pageof 38
Expert Opinion on Biological Therapy|December 23, 2011
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical managementMauro Viganò, Elisabetta Degasperi, Alessio Aghemo, et al.
Journal of Hepatology|September 25, 2009
HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis CStella De Nicola, Alessio Aghemo, Maria Grazia Rumi, et al.
Thrombosis Research|October 20, 2006
Endothelial protein C receptor plasma levels increase in chronic liver disease, while thrombomodulin plasma levels increase only in hepatocellular carcinomaEugenia Biguzzi, Franca Franchi, Paolo Bucciarelli, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 12, 2020
A letter of solidarity during the COVID-19 pandemicJeffrey V Lazarus, Francesco Negro, Manal El-Sayed, et al.
Hepatology (Baltimore, Md.)|September 3, 2010
Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapyAlessio Aghemo, Maria Grazia Rumi, Stella De Nicola, et al.
Hepatology (Baltimore, Md.)|January 30, 2009
The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?Alessio Aghemo, Maria Grazia Rumi, Gian Maria Prati, et al.
Seminars in Liver Disease|February 29, 2020
Postsustained Virological Response Management in Hepatitis C PatientsChiara Masetti, Ana Lleo, Matteo Colombo, et al.
Expert Review of Anti-Infective Therapy|May 1, 2013
PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year historyElisabetta Degasperi, Mauro Viganò, Alessio Aghemo, et al.
Therapeutic Advances in Medical Oncology|July 20, 2019
The risk of liver cancer in autoimmune liver diseasesAna Lleo, Ynto S de Boer, Rodrigo Liberal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 19, 2016
Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literatureRoberta D'Ambrosio, Alessio Aghemo, Valeria Rossetti, et al.
Pageof 38